A federal judge has dismissed all claims against GlaxoSmithKline in the Wellbutrin XL antitrust litigation in which the pharmaceutical giant was accused of delaying the entry of generic versions of the antidepressant medication to market by entering into illegal agreements with generic drug makers to settle patent infringement lawsuits.

U.S. District Judge Mary A. McLaughlin of the Eastern District of Pennsylvania granted GSK's motion for summary judgment on all claims Wednesday. The litigation was initiated by direct and indirect purchasers of Wellbutrin in 2008. Those plaintiffs argued the Wellbutrin settlement was anti-competitive in nature.

However, McLaughlin said in the court's opinion that the benefits of the settlement outweighed the negatives.